Items where authors include "Sheridan, R."

Article

Abani, O., Abbas, A., Abbas, F. et al. (7724 more authors) (2025) Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Knapp, P., Bower, P., Lidster, A. et al. (6 more authors) (2025) Why do patients take part in research? An updated overview of systematic reviews of psychosocial barriers and facilitators. Trials, 26. 174. ISSN 1468-6708

Knapp, P. orcid.org/0000-0001-5904-8699, Bower, P., Lidster, A. et al. (6 more authors) (2025) Why do patients take part in research? An updated overview of systematic reviews of psychosocial barriers and facilitators. Trials, 26. 174. ISSN 1745-6215

Abani, O., Abbas, A., Abbas, F. et al. (8041 more authors) (2025) Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine, 81. 103080. ISSN 2589-5370

Towns, C. orcid.org/0000-0001-8418-6241, Fang, Z.-H. orcid.org/0000-0002-0225-8772, Tan, M.M.X. orcid.org/0000-0001-5835-669X et al. (79 more authors) (2024) Parkinson’s families project: a UK-wide study of early onset and familial Parkinson’s disease. npj Parkinson's Disease, 10. 188. ISSN 2373-8057

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Sandercock, P., Darbyshire, J., DeMets, D. et al. (2050 more authors) (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 15. 924. ISSN 2041-1723

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Lee, I.T., Cosgrove, C.A., Moore, P. et al. (63 more authors) (2023) Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. The Lancet Infectious Diseases, 23 (9). pp. 1007-1019. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Liu, X., Munro, A.P., Feng, S. et al. (56 more authors) (2023) Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]. Journal of Infection, 86 (5). pp. 540-541. ISSN 0163-4453

Munro, A.P.S., Feng, S., Janani, L. et al. (362 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. The Lancet Infectious Diseases, 22 (8). pp. 1131-1141. ISSN 1473-3099

Liu, X., Munro, A.P.S., Feng, S. et al. (56 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. Journal of Infection, 84 (6). pp. 795-813. ISSN 0163-4453